Biogen discontinues Apellis programs post $5.6B acquisition, reallocating resources to Empaveli and Syfovre. U.S. begins ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results